CG
ABCL icon

Cutler Group’s AbCellera Biologics ABCL Stock Holding History

Cutler Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-105,700
Closed -$52K – 4278
2022
Q3 		$52K Buy
105,700
+3,000
+3% +$32.9K ﹤0.01% 1856
2022
Q2 		$223K Buy
102,700
+71,700
+231% +$607K 0.02% 938
2022
Q1 		$15K Buy
31,000
+25,300
+444% +$240K ﹤0.01% 3259
2021
Q4 		$2K Sell
5,700
-8,600
-60% -$131K ﹤0.01% 4642
2021
Q3 		$11K Buy
14,300
+1,900
+15% +$33.6K ﹤0.01% 3817
2021
Q2 		$27K Buy
12,400
+8,800
+244% +$243K ﹤0.01% 3031
2021
Q1 		$15K Buy
+3,600
New +$143K ﹤0.01% 3421

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's ABCL Position: Q1 2023 in Review

Cutler Group sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 9,400 shares — an estimated $95K sold.

Cutler Group first reported a position in ABCL in Q1 2021 and held it in 7 quarters. The position peaked at $95K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

  • Cutler Group reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 9,400 AbCellera Biologics shares in Q1 2023, an estimated $95K.
  • Cutler Group first reported a position in AbCellera Biologics in Q1 2021 and held it in 7 quarters.
  • Cutler Group's AbCellera Biologics position peaked at $95K in Q4 2022.
  • 183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.